Author

Timothy J. Guzi

Observed names: T J Guzi, T. Guzi, T. J. GUZI, Tim Guzi, Timothy Guzi, Timothy Guzi (6618530)

Institution: Blueprint Medicines (United States)

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Blueprint Medicines (United States), University of Virginia

ORCID: 0009-0004-7458-4245

Observed ORCID: 0009-0004-7458-4245

OpenAlex ID: A5103047843

Rational design and molecular effects of a new topoisomerase II inhibitor, azatoxin.

1992 · F Leteurtre, J Madalengoitia, et al. · PubMed · 72

Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2

2007 · Kamil Paruch, Michael P. Dwyer, et al. · Bioorganic & Medicinal Chemistry Letters · 69

1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC

2020 · S.S. Schalm, T. Dineen, et al. · Annals of Oncology · 54

Abstract 1262: BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC

2021 · Chiara Conti, John Campbell, et al. · Cancer Research · 29

An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva

2024 · Alison J. Davis, Natasja Brooijmans, et al. · Science Translational Medicine · 27

Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma

2022 · Stefanie S. Schalm, Erin O’Hearn, et al. · Gastro Hep Advances · 21

384P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC

2020 · S.S. Schalm, T. Dineen, et al. · Annals of Oncology · 13

Abstract 1717: MAP4K1 inhibition enhances immune cell activation and anti-tumor immunity in preclinical tumor models

2021 · Kerrie Faia, Alberto Toso, et al. · Cancer Research · 3

Phe19 modification of HDM2-p53 PPI inhibitors to alleviate CYP3A4 metabolism/mechanism-based inhibition liability

2022 · Yuan Tian, Brian R. Lahue, et al. · Bioorganic & Medicinal Chemistry Letters · 1

Abstract B127: Evaluating PRKACA as a therapeutic target for Fibrolamellar Carcinoma

2019 · Stefanie S Schalm, Erin O’Hearn, et al. · Molecular Cancer Therapeutics

Crystal Structure of FGFR4 with an Irreversible Inhibitor

2014 · J.L. Kim, C. Miduturu, et al. · Worldwide Protein Data Bank

ChemInform Abstract: Syntheses of 5′‐Amino‐2′,5′‐dideoxy‐2′,2′‐difluorocytidine Derivatives as Novel Anticancer Nucleoside Analogues.

2014 · Marc A. Labroli, Michael P. Dwyer, et al. · ChemInform

Novel pyrazolopyrimidines as novel cyćlin dependent kinase inhibitors

2008 · Timothy Guzi, Kamil Paruch, et al.

ChemInform Abstract: A Novel Synthesis of Piperidin‐3‐ones via an Intramolecular Amadori‐ Type Reaction.

1996 · T. J. GUZI, T. L. MACDONALD · ChemInform

Works count: 15

Citation count: 289

H-index: 7

I10-index: 7